Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06017258 · ClinicalTrials.gov registry record · Phase 1

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

A Phase 1 study of Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
15
Enrollment target
7
Study locations

NCT06017258 is a Phase 1 study of Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 15 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (87% lower). The trial reports 7 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06017258, a Phase 1 study of Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

Conditions Studied

Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia Refractory Relapsed Acute Myeloid Leukemia

Interventions

  • BIOLOGICAL CD371-specific/YSNVz/I-18 CAR T cells

Study Locations (7)

New York

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All protocol activites) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-08-22
Est. Completion 2026-08-22
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06017258

The ClinicalTrials.gov registry entry for NCT06017258 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (87% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which CD371-specific/YSNVz/I-18 CAR T cells is the first listed.

NCT06017258 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06017258 about?

NCT06017258 is a clinical study titled "A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia". The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

What is the current status of trial NCT06017258?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-08-22. Estimated completion is 2026-08-22.

What conditions does trial NCT06017258 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Relapsed Acute Myeloid Leukemia.

What interventions are being tested in trial NCT06017258?

The interventions under investigation include: CD371-specific/YSNVz/I-18 CAR T cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT06017258?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06017258 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Refractory Acute Myeloid Leukemia

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.